Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Clinical Features, Management and Prognostic Factors of Patients with Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

Yizhen Liu, Lingyu Liu, Chuanxu Liu, Wenhao Zhang, Shiyu Jiang, Qunling Zhang, Fangfang Lyu, Xiaojian Liu, Junning Cao, Xuejun Ma, Rong Tao

Blood (2024) 144 (Supplement 1): 1653.

https://doi.org/10.1182/blood-2024-202237

Published: 2024

Journal Articles

Phase II Clinical Trial on Chidamide, Rituximab and High-Dose Methotrexate (C-R-HDMTX) in Newly Diagnosed Primary CNS Lymphoma

Guang-Liang Chen, Jia Jin, Hui Sun, Yizhen Liu, Qunling Zhang, Zuguang Xia, Junning Cao, Xiaonan Hong, Fangfang Lv

Blood (2024) 144 (Supplement 1): 6526.

https://doi.org/10.1182/blood-2024-194111

Published: 2024

Journal Articles

Proteogenomic Features Define Novel Subtypes of Mantle Cell Lymphoma

Yuting Yan, Xinzhou Ge, Jian Sun, Lei Yu, Qunling Zhang, Ying Yu, Zhenyu Jia, Dehui Zou, Jessica Li, Lugui Qiu, Lili Wang, Shuhua Yi

Blood (2023) 142 (Supplement 1): 4368.

https://doi.org/10.1182/blood-2023-190838

Published: 2023

Journal Articles

A Phase II Study of Chidamide Plus R-GDP Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Transplantation: Efficacy and Safety Analysis

Guangliang Chen, Kai Xue, Qunling Zhang, Jia Jin, Yizhen Liu, Zuguang Xia, Fangfang Lyu, Xiaonan Hong, Xiaoqiu LI, Junning Cao

Blood (2023) 142 (Supplement 1): 5805.

https://doi.org/10.1182/blood-2023-174307

Published: 2023

Journal Articles

Clinical Predictors of Central Nervous System Relapse in Primary Breast Diffuse Large B-Cell Lymphoma

Guang-Liang Chen, Pin Guo, Shiyu Jiang, Juan J. Gu, Qunling Zhang, Yizhen Liu, Junning Cao, Xiaonan Hong, Rong TAO, Fangfang Lv

Blood (2022) 140 (Supplement 1): 3790–3791.

https://doi.org/10.1182/blood-2022-156877

Published: 2022

Journal Articles

Preliminary Result of Lenalidomide Combined with R-CHOP(R2-CHOP) in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma: A Prospective Phase II Clinical Trial

Yizhen Liu, Qunling Zhang, Fangfang Lv, Xiaojian Liu, Dongmei Ji, Zuguang Xia, Jia Jin, Rong TAO, Wenhao Zhang, Xiaoqiu Li, Shengjian Zhang, Jiachen Wang, Xiaonan Hong, Junning Cao

Blood (2022) 140 (Supplement 1): 6627–6628.

https://doi.org/10.1182/blood-2022-158657

Published: 2022

Journal Articles

Soluble ICAM-1 As Effective Serologic Marker to Predict Clinical Outcome for Early -Stage I/II Nasal Natural Killer /T-Cell Lymphoma

Juan J Gu, Paola Ghione, Shiyu Jiang, Cory Mavis, Francisco J. Hernandez-Ilizaliturri, Dongmei Ji, Junning Cao, Xiaonan Hong, Xuejun Ma, Qunling Zhang

Blood (2021) 138 (Supplement 1): 4542.

https://doi.org/10.1182/blood-2021-149229

Published: 2021

Journal Articles

Inhibitor of DNA Binding 3 Is a Potential Prognostic Biomarker in Non-GCB Diffuse Large B-Cell Lymphoma

Qunling Zhang, Jichuan Wu, Juan J. Gu, Yizhen Liu, Zuguang Xia, Lan Wang, Xiaonan Hong, Junning Cao

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-141887

Published: 2020

Journal Articles

SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS

Blood (2020) 135 (25): 2271–2285.

https://doi.org/10.1182/blood.2019001963

Published: 2020

Includes: Supplemental data

Journal Articles

Hexokinase II Expression As a Prognosis Marker in Diffuse Large B-Cell Lymphoma (DLBCL) Pre- and Post- the Incorporation of Rituximab to Standard CHOP Chemotherapy

Juan J. Gu, MD PhD, Yizhen Liu, MD PhD, Jia Jin, Ling Yang, Zuguang Xia, Xiaojian Liu, Fangfang Lv, MD, Francisco J. Hernandez-Ilizaliturri, MD, Xiaonan Hong, Junning Cao, MD, Qunling Zhang, MD PhD

Blood (2019) 134 (Supplement_1): 5233.

https://doi.org/10.1182/blood-2019-128878

Published: 2019

Journal Articles

Deubiquitinase OTUD7B Is Potential Prognostic Biomarker in Diffuse Large B-Cell Lymphoma

Qunling Zhang, MD PhD, Juan Gu, MD PhD, Kai Xue, MD, Zuguang Xia, Cory Mavis, BSc, MSc, Francisco J. Hernandez-Ilizaliturri, MD, Ye Guo, Xiaonan Hong, Junning Cao, MD

Blood (2018) 132 (Supplement 1): 4239.

https://doi.org/10.1182/blood-2018-99-118872

Published: 2018

Journal Articles

The Three E Proteins Define a Heterogeneity of the AML1-ETO-Containing Transcription Factor Complex (AETFC) and Differentially Regulate t(8;21) Leukemogenesis

Blood (2018) 132 (Supplement 1): 5247.

https://doi.org/10.1182/blood-2018-99-112372

Published: 2018

Journal Articles

Protein Kinase C Delta in Diffuse Large B-Cell Lymphoma Post-Rituximab Era: Potential Prognostic Marker in Germinal Center B-Cell Lymphoma

Qunling Zhang, MD PhD, Juan Gu, MD PhD, Kai Xue, MD, Cory Mavis, BSc, MSc, Francisco J. Hernandez-Ilizaliturri, MD, Junning Cao, Xiaonan Hong, Ye Guo

Blood (2017) 130 (Supplement 1): 2839.

https://doi.org/10.1182/blood.V130.Suppl_1.2839.2839

Published: 2017

Journal Articles

The Adhesion Molecule ICAM-1 in Diffuse Large B-Cell Lymphoma Post-Rituximab Era: Relationship with Prognostic Importance and Rituximab Resistance

Qunling Zhang, MD PhD, Juan J Gu, PhD, Cory Mavis, MSc, Ye Guo, MD, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2016) 128 (22): 4212.

https://doi.org/10.1182/blood.V128.22.4212.4212

Published: 2016

Journal Articles

JQ1, a c-MYC Inhibitor Targets Hexokinase II and Enhances the Cytotoxic Effects of Chemotherapeutic Agents in Diffuse Large B-Cell Lymphoma (DLBCL)

Juan J Gu, PhD, Matthew J. Barth, MD, Qunling Zhang, MD PhD, Cory Mavis, MSc, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2016) 128 (22): 5378.

https://doi.org/10.1182/blood.V128.22.5378.5378

Published: 2016

Journal Articles

Palbociclib (PD-0332991), a Potent Selective CDK4/6 Inhibitor, Overcomes Therapy-Resistant and Sensitizes Diffuse Large B-Cell Lymphoma Pre-Clinical Models to Chemo-Reagents

Juan J Gu, PhD, Qunling Zhang, MD PhD, Cory Mavis, MSc, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2015) 126 (23): 3997.

https://doi.org/10.1182/blood.V126.23.3997.3997

Published: 2015

Journal Articles

Dual Inhibition of PKC Delta By Carfilzomib (CFZ) and Ibrutinib Results in Synergistic Activity in Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Pre-Clinical Models and in Primary Tumor Cells Isolated from B-Cell Lymphoma Patients

Qunling Zhang, MD PhD, Juan J Gu, PhD, Ye Guo, MD, Jacob Klos, Cory Mavis, MSc, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2015) 126 (23): 4006.

https://doi.org/10.1182/blood.V126.23.4006.4006

Published: 2015

Journal Articles

Metformin Induces p53-Dependent Mitochondrial Stress in Therapy-Sensitive and -Resistant Lymphoma Pre-Clinical Model and Primary Patients Sample with B-Cell Non-Hodgkin Lymphoma (NHL)

Juan J Gu, PhD, Qunling Zhang, MD PhD, Cory Mavis, MSc, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2015) 126 (23): 4008.

https://doi.org/10.1182/blood.V126.23.4008.4008

Published: 2015

Journal Articles

JQ1, a Potent c-MYC Inhibitor Overcomes Rituximab-Chemotherapy Resistance in Lymphoma Pre-Clinical Models

Juan J Gu, PhD, Qunling Zhang, MD PhD, Cory Mavis, MSc, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2015) 126 (23): 2761.

https://doi.org/10.1182/blood.V126.23.2761.2761

Published: 2015

Journal Articles

Elevated High Sensitivity Troponin T (HsTnT) during Front-Line Therapy with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone +/- Rituximab (CHOP+/-R) or Cyclophosphamide, Epirubicin, Vincristine and Prednisone +/- Rituximab (CEpOP+/-R) Correlates with a Decline in Left Ventricular Ejection Fraction (LVEF) in Patients with Aggressive B-Cell Lymphoma: Results from a Randomized Prospective Clinical Trial NCT00854568

Kai Xue, MD, Juan J Gu, PhD, Qunling Zhang, MD, Xiaojian Liu, MD, Jiachen Wang, Jianfeng Luo, Francisco J. Hernandez-Ilizaliturri, MD, Stanley F. Fernandez, MD, Myron S. Czuczman, MD, Junning Cao, MD Associate Professor, Xiaonan Hong, MD, Ye Guo, MD

Blood (2014) 124 (21): 3041.

https://doi.org/10.1182/blood.V124.21.3041.3041

Published: 2014

NARROW

Clinical Features, Management and Prognostic Factors of Patients with Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

Phase II Clinical Trial on Chidamide, Rituximab and High-Dose Methotrexate (C-R-HDMTX) in Newly Diagnosed Primary CNS Lymphoma

Proteogenomic Features Define Novel Subtypes of Mantle Cell Lymphoma

A Phase II Study of Chidamide Plus R-GDP Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Ineligible for Autologous Transplantation: Efficacy and Safety Analysis

Clinical Predictors of Central Nervous System Relapse in Primary Breast Diffuse Large B-Cell Lymphoma

Preliminary Result of Lenalidomide Combined with R-CHOP(R2-CHOP) in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma: A Prospective Phase II Clinical Trial

Soluble ICAM-1 As Effective Serologic Marker to Predict Clinical Outcome for Early -Stage I/II Nasal Natural Killer /T-Cell Lymphoma

Inhibitor of DNA Binding 3 Is a Potential Prognostic Biomarker in Non-GCB Diffuse Large B-Cell Lymphoma

SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS

Hexokinase II Expression As a Prognosis Marker in Diffuse Large B-Cell Lymphoma (DLBCL) Pre- and Post- the Incorporation of Rituximab to Standard CHOP Chemotherapy

Deubiquitinase OTUD7B Is Potential Prognostic Biomarker in Diffuse Large B-Cell Lymphoma

The Three E Proteins Define a Heterogeneity of the AML1-ETO-Containing Transcription Factor Complex (AETFC) and Differentially Regulate t(8;21) Leukemogenesis

Protein Kinase C Delta in Diffuse Large B-Cell Lymphoma Post-Rituximab Era: Potential Prognostic Marker in Germinal Center B-Cell Lymphoma

The Adhesion Molecule ICAM-1 in Diffuse Large B-Cell Lymphoma Post-Rituximab Era: Relationship with Prognostic Importance and Rituximab Resistance

JQ1, a c-MYC Inhibitor Targets Hexokinase II and Enhances the Cytotoxic Effects of Chemotherapeutic Agents in Diffuse Large B-Cell Lymphoma (DLBCL)

Palbociclib (PD-0332991), a Potent Selective CDK4/6 Inhibitor, Overcomes Therapy-Resistant and Sensitizes Diffuse Large B-Cell Lymphoma Pre-Clinical Models to Chemo-Reagents

Dual Inhibition of PKC Delta By Carfilzomib (CFZ) and Ibrutinib Results in Synergistic Activity in Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Pre-Clinical Models and in Primary Tumor Cells Isolated from B-Cell Lymphoma Patients

Metformin Induces p53-Dependent Mitochondrial Stress in Therapy-Sensitive and -Resistant Lymphoma Pre-Clinical Model and Primary Patients Sample with B-Cell Non-Hodgkin Lymphoma (NHL)

JQ1, a Potent c-MYC Inhibitor Overcomes Rituximab-Chemotherapy Resistance in Lymphoma Pre-Clinical Models

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only